Search in:

Advanced search

Scandinavian Journal of Urology Volume 55, 2021 - Issue 1

Journal homepage

Open access

5,028

Views

CrossRef citations to date

Altmetric

Articles

Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study in Sweden

Johanna Svenssona Astellas Pharma a/s – Nordic Operations, Kastrup, DenmarkCorrespondence[email protected]
View further author information

Ingela Franck Lissbrantb Department of Oncology, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden

https://orcid.org/0000-0001-8612-9814 View further author information

Oskar Gauffinc Department of Surgical Sciences, Uppsala University Hospital, Uppsala, SwedenView further author information

Marie Hjälm-Erikssond Department of Oncology and Pathology, Capio St. Göran’s Hospital, Karolinska Institute, Stockholm, SwedenView further author information

Suzanne Kilanya Astellas Pharma a/s – Nordic Operations, Kastrup, DenmarkView further author information

Karin Fagerlunda Astellas Pharma a/s – Nordic Operations, Kastrup, DenmarkView further author information

Pär Stattinc Department of Surgical Sciences, Uppsala University Hospital, Uppsala, Sweden

https://orcid.org/0000-0002-8306-0687 View further author information

show all

Pages 1-8 | Received 01 Sep 2020, Accepted 12 Nov 2020, Published online: 10 Dec 2020

Cite this article
https://doi.org/10.1080/21681805.2020.1851762
CrossMark

Full Article
Figures & data
References
Supplemental
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF View EPUB EPUB

References

NORDCAN. Cancer stat fact sheets; Nordic countries – Prostate; 2019 [cited 2019 Dec 16]. Available from: http://www-dep.iarc.fr/NORDCAN/english/StatsFact.asp?cancer=261&country=0.
Google Scholar
NORDCAN. Nordic countries (end of 2016). Prevalence, male, age 0–85+; 2019 [cited 2019 Dec 16]. Available from: http://www-dep.iarc.fr/NORDCAN/english/table13.asp?registry=0&period=2016&sex=1&stat=2&age_from=1&age_to=18&sort=2&submit=Execute.
Google Scholar
Westerberg M, Franck Lissbrant I, Damber JE, et al. Temporal changes in survival in men with de novo metastatic prostate cancer: nationwide population-based study. Acta Oncol. 2020;59(1):106–111.
PubMed Web of Science ®Google Scholar
Cattrini C, Castro E, Lozano R, et al. Current treatment options for metastatic hormone-sensitive prostate cancer. Cancers. 2019;11(9):1355.
PubMed Web of Science ®Google Scholar
Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013;32(49):5501–5511.
PubMed Web of Science ®Google Scholar
NORDCAN. Cancer stat fact sheets; Sweden – Prostate; 2019 [cited 2019 Dec 16]. Available from: http://www-dep.iarc.fr/NORDCAN/english/StatsFact.asp?cancer=261&country=752.
Google Scholar
Moussa M, Papatsoris A, Abou Chakra M, et al. Pharmacotherapeutic strategies for castrate-resistant prostate cancer. Expert Opin Pharmacother. 2020;21(12):1431–1448.
PubMed Web of Science ®Google Scholar
Franck Lissbrant I, Garmo H, Widmark A, et al. Population-based study on use of chemotherapy in men with castration resistant prostate cancer. Acta Oncol. 2013;52(8):1593–1601.
PubMed Web of Science ®Google Scholar
Franck Lissbrant I, Ventimiglia E, Robinson D, et al. Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden. Scand J Urol. 2018;52(2):143–150.
PubMed Web of Science ®Google Scholar
Van Hemelrijck M, Garmo H, Wigertz A, et al. Cohort Profile Update: The National Prostate Cancer Register of Sweden and Prostate Cancer Data base—a refined prostate cancer trajectory. Int J Epidemiol. 2016;45(1):73–82.
PubMed Web of Science ®Google Scholar
Franck Lissbrant I, Hjälm Eriksson M, Lambe M, et al. Set-up and preliminary results from the Patient-overview Prostate Cancer. Longitudinal registration of treatment of advanced prostate cancer in the National Prostate Cancer Register of Sweden. Scand J Urol. 2020;54(3):227–234.
PubMed Web of Science ®Google Scholar
Socialstyrelsen. Viktlistor för NordDRG; 2019 [cited 2019 Dec 16]. Available from: https://www.socialstyrelsen.se/utveckla-verksamhet/e-halsa/klassificering-och-koder/drg/viktlistor/.
Google Scholar
Region Skåne. Avgifter och prislistor; 2019 [cited 2019 Dec 16]. Available from: https://vardgivare.skane.se/patientadministration/avgifter-och-prislistor/.
Google Scholar
Södra sjukvårdsregionen. Regionala priser och ersättningar föregående år; 2019 [cited 2019 Dec 16]. Available from: https://sodrasjukvardsregionen.se/verksamhet/avtal-priser/regionala-priser-och-ersattningar-foregaende-ar/.
Google Scholar
Södra sjukvårdsregionen. Prislista för sydöstra sjukvårdsregionen; 2019 [cited 2019 Dec 16]. Available from: https://plus.rjl.se/infopage.jsf?nodeId=41089.
Google Scholar
Grochtdreis T, Konig HH, Dobruschkin A, et al. Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: a systematic review. PLoS One. 2018;13(12):e0208063.
PubMed Web of Science ®Google Scholar
Fizazi K, Tran N, Fein L, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(5):686–700.
PubMed Web of Science ®Google Scholar
Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36(11):1080–1087.
PubMed Web of Science ®Google Scholar
Clarke NW, Ali A, Ingleby FC, et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol. 2019;30(12):1992–2003.
PubMed Web of Science ®Google Scholar
Helgstrand JT, Røder MA, Klemann N, et al. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer—A population-based analysis of 2 national cohorts. Cancer. 2018;124(14):2931–2938.
PubMed Web of Science ®Google Scholar
Bandini M, Pompe RS, Marchioni M, et al. Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study. Int Urol Nephrol. 2018;50(1):71–78.
PubMed Web of Science ®Google Scholar
Aly M, Leval A, Schain F, et al. Survival in patients diagnosed with castration-resistant prostate cancer: a population-based observational study in Sweden. Scand J Urol. 2020;54(2):115–121.
PubMed Web of Science ®Google Scholar
Tomic K, Sandin F, Wigertz A, et al. Evaluation of data quality in the National Prostate Cancer Register of Sweden. Eur J Cancer. 2015;51(1):101–111.
PubMed Web of Science ®Google Scholar
Tomic K, Berglund A, Robinson D, et al. Capture rate and representativity of The National Prostate Cancer Register of Sweden. Acta Oncol. 2015;54(2):158–163.
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study in Sweden

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study in Sweden

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date